In Pennsylvania’s first precedent-setting decision regarding hormone replacement therapy mass tort litigation, the Superior Court has revived a plaintiff’s lawsuit by finding that the plaintiff was entitled to an exception to the two-year statute of limitations because she couldn’t have reasonably known of an alleged link between her breast cancer and HRT drugs before the publication of a widely publicized study.
Despite a $1.5 million verdict in favor of plaintiff Merle Simon, Simon’s lawsuit was dismissed because of the judgment notwithstanding the verdict granted by Philadelphia Common Pleas Judge Nitza Quinones Alejandro.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
